Dr. Rodolfo Hurle and co-workers showed, in their phase I multicentric international study, that Oncofid-P-B development by Fidia Farmaceutici S.p.A. (Italy), may be considered an innovative compound for the treatment of high-risk and very high-risk nonmuscle-invasive bladder cancer (NMIBC).1 Oncofid-P-B results from the chemical conjugation of paclitaxel with hyaluronic acid (HA). HA has been studied for a long time from urologists and it was used for the treatment of urinary tract infection, interstitial cystitis, and late radiation induced cystitis.2 Hurle’s report opens a new scenario. One of the main functions of urologists, who are involved in the management of bladder cancer, is to discover and deliver safe, effective, and affordable treatments to patients, based on their personalized needs. The treatment of high-risk and very high-risk NMIBC remains challenging. Preliminary results showed that Oncofid offers a new paradigm for how to manage those patients.